Sanofi Consumer Q1 Results | Net profit falls 20% to ₹50 crore, revenue slides 22% to ₹173 crore

French drug major Sanofi Consumer Healthcare India Ltd on Friday (May 2) reported a 20.3% year-on-year (YoY) decline in net profit at ₹50 crore for the first quarter that ended March 31, 2025.

In the corresponding quarter of the previous fiscal, Sanofi Consumer Healthcare India posted a net profit of ₹62.7 crore, the company said in a regulatory filing.

The company's revenue from operations dropped 22.1% to ₹172.6 crore as against ₹221.6 crore in the corresponding period of the preceding fiscal. At the operating level, EBITDA fell 21.8% to ₹64 crore in the fourth quarter of this fiscal over ₹81.8 crore in the corresponding period in the previous fiscal.

Also Read: Sanofi India Managing Director Rodolfo Hrosz to step down, effective April 30

EBITDA margin stood at 37.1% in the reporting quarter as compared to 36.9% in the corresponding period in the previous fiscal. EBITDA is earnings before interest, tax, depreciation, and amortisation.

The Q1 2025 also witnessed a successful launch of Allegra D, an addition to the existing portfolio of Allegra variants in India; a brand with over 25 years legacy in India. Q1 2025 and Q1 2024 are not directly comparable due to the demerger and voluntary product recall of certain variants of key brands.

Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited, “We continue to focus on strengthening our operations and continue to bring superior, simple and accessible products that enable consumers to control their own health. Our commitment to delivering high-quality, science-backed products remains at the core of our integrated growth strategy."

Also Read: Sanofi India Q4 revenue, EBITDA rise; ₹117 final dividend recommended

The results came after the close of the market hours. Shares of Sanofi Consumer Healthcare India Ltd ended at ₹4,940.00, down by ₹2.35 or 0.048% on the BSE.